Elanco Animal Health (ELAN) Stock Price, News & Analysis

Company Overview

Elanco Animal Health Inc. is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018. Since then, Elanco has pursued strategic acquisitions to strengthen its global footprint and expand its R&D capabilities. A notable milestone was the 2020 acquisition of Bayer’s Animal Health business, which added complementary products and bolstered Elanco’s presence across Europe, Latin America, Asia-Pacific and North America.

Elanco operates a network of research centers, manufacturing sites and distribution facilities around the world, enabling it to serve customers in more than 90 countries. The company invests in collaborations with universities, industry partners and veterinarians to advance its pipeline of biologics and pharmaceuticals. Under the leadership of President and Chief Executive Officer Jeffrey Simmons, Elanco continues to focus on innovation, sustainability and responsible use of medicines to address emerging health challenges in animal agriculture and companion care.

Key Stats

• Today's Range: $24.76 to $25.29
• 50-Day Range: $19.78 to $26.21
• 52-Week Range: $13.39 to $27.72
• Volume: 4.23 million shs
• Average Volume: 4.67 million shs
• Market Capitalization: $12.55 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.55
• Consensus Rating: Moderate Buy

Elanco Animal Health Stock Analysis - MarketRank™

Elanco Animal Health scored higher than 72% of companies evaluated by MarketBeat, and ranked 164th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Elanco Animal Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Elanco Animal Health has a consensus price target of $28.55, representing about 13.6% upside from its current price of $25.12.

Amount of Analyst Coverage

Elanco Animal Health has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.91%

Earnings Growth

Earnings for Elanco Animal Health are expected to grow by 9.91% in the coming year, from $1.11 to $1.22 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elanco Animal Health is -50.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elanco Animal Health is -50.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Elanco Animal Health has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Elanco Animal Health has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.20% of the float of Elanco Animal Health has been sold short.

Short Interest Ratio / Days to Cover

Elanco Animal Health has a short interest ratio ("days to cover") of 6.41.

Change versus previous month

Short interest in Elanco Animal Health has recently increased by 7.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elanco Animal Health does not currently pay a dividend.

Dividend Growth

Elanco Animal Health does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Elanco Animal Health has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Elanco Animal Health this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for ELAN on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.

MarketBeat Follows

6 people have added Elanco Animal Health to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Elanco Animal Health in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $199,806.00 in company stock, which represents 0.0016% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Elanco Animal Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $199,806.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.14% of the stock of Elanco Animal Health is held by insiders.

Percentage Held by Institutions

97.48% of the stock of Elanco Animal Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ELAN
• CIK: 1739104
• Web: www.elanco.com
• Phone: (877) 352-6261
• Fax: N/A
• Employees: 9,400
• Year Founded: 1954

Price Target and Rating

• Average Price Target for Elanco Animal Health: $28.55
• High Price Target: $32.00
• Low Price Target: $23.00
• Potential Upside/Downside: +13.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.77
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 22.63
• P/E Growth: 1.63
• Net Income: -$232 million
• Net Margins: -4.95%
• Pretax Margin: -4.03%
• Return on Equity: 7.42%
• Return on Assets: 3.66%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 2.16
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: $4.72 billion
• Price / Sales: 2.66
• Cash Flow: $2.33 per share
• Price / Cash Flow: 10.77
• Book Value: $13.18 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 499,450,000
• Free Float: 493,756,000
• Market Cap: $12.55 billion
• Optionable: Optionable
• Beta: 1.68